moxifloxacin has been researched along with trovafloxacin in 51 studies
Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (trovafloxacin) | Trials (trovafloxacin) | Recent Studies (post-2010) (trovafloxacin) |
---|---|---|---|---|---|
3,157 | 552 | 1,690 | 466 | 47 | 43 |
Protein | Taxonomy | moxifloxacin (IC50) | trovafloxacin (IC50) |
---|---|---|---|
Thromboxane-A synthase | Homo sapiens (human) | 4.023 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (17.65) | 18.2507 |
2000's | 35 (68.63) | 29.6817 |
2010's | 5 (9.80) | 24.3611 |
2020's | 2 (3.92) | 2.80 |
Authors | Studies |
---|---|
Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
Anquetin, G; Derouin, F; Farhati, K; Gozalbes, R; Greiner, J; Guedj, R; Mahmoudi, N; Rouquayrol, M; Santillana-Hayat, M; Vierling, P | 1 |
Jolivette, LJ; Ward, KW | 1 |
Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
Ho, YR; Hung, KH; Janapatla, RP; Wu, CW; Wu, HM; Wu, JJ; Yan, JJ | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Acar Çevik, U; Gençer, HK; Ilgın, S; Levent, S; Özkay, Y | 1 |
Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
Brady, SF; Koirala, B; Peek, J | 1 |
Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R | 1 |
Bauernfeind, A | 1 |
Hoban, DJ; Karlowsky, JA; Zhanel, GG | 1 |
Dalhoff, A; Hoppe, JE; Pfründer, D | 1 |
Laverdiere, M; Restieri, C; Weiss, K | 1 |
Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
Peters, G; von Eiff, C | 1 |
Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
Betriu, C; Gómez, M; Palau, ML; Picazo, JJ; Sánchez, A | 1 |
Eiffert, H; Mäder, M; Nau, R; Schmidt, H; Stuertz, K; Trostdorf, F | 1 |
Beyer, R; Millichap, JJ; Noskin, GA; Pestova, E; Peterson, LR; Stosor, V | 1 |
Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C | 1 |
Bjarnason, J; Blondeau, JM; Laskowski, R; Stewart, C | 1 |
Betriu, C; Boloix, A; Culebras, E; Gómez, M; Palau, ML; Picazo, JJ; Redondo, M; Sánchez, A | 1 |
Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
Coleman, EJ; Mandell, GL | 1 |
Chen, YC; Ho, SW; Hsueh, PR; Lu, JJ; Luh, KT; Pan, HJ; Teng, LJ; Wu, JJ | 1 |
Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W | 1 |
Doern, GV; Ernst, EJ; Klepser, ME; Petzold, CR; Rhomberg, P | 1 |
Barzilai, A; Diamantstein, L; Gruzman, G; Keller, N; Rubinovitch, B; Rubinstein, E; Yoseph, G | 1 |
Adrián, F; del Campo, R; García, C; Gómez-Lus, P; Gómez-Lus, R; Rubio, MC; Sánchez, S | 1 |
Appelbaum, PC; Davies, TA; Dewasse, BE; Jacobs, MR; Nagai, K | 1 |
Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V | 1 |
Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I | 1 |
Appelbaum, PC; Bozdogan, B; Clark, CL; Davies, TA; Dewasse, B; Jacobs, MR; Nagai, K | 1 |
Goldstein, EJ | 1 |
Finegold, S; Goldstein, E; Gorbach, SL; Harrell, L; Hecht, DW; Jacobus, NV; Jenkins, S; McDermott, LA; Pierson, C; Rihs, J; Ruthazer, R; Snydman, DR; Venezia, R | 1 |
Arvis, P; Klossek, JM; Leberre, MA; Nikolaidis, P; Siegert, R | 1 |
Dalhoff, A; Shalit, I | 1 |
Aguilar, L; Garcia-Mendez, E; Jiménez De Anta, MT; Marco, F; Mensa, J; Ruiz, J; Sierra, JM; Vila, J | 1 |
Choudhri, S; Church, D; Grossman, C; Haverstock, D; Herman-Gnjidic, Z; Lode, H; McGivern, J | 1 |
Schooley, S; Stein, GE | 1 |
Cabeza, JG; Hernandez, J; Llagostera, M; Mensa, J; Montero, T; Ruiz Chaler, M; Sierra, JM; Vila, J | 1 |
Betriu, C; Culebras, E; Gómez, M; Picazo, JJ; Rodríguez-Avial, I | 1 |
3 review(s) available for moxifloxacin and trovafloxacin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Quinolone antibiotics.
Topics: | 2019 |
Immunomodulatory effects of quinolones.
Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clinical Trials as Topic; Cytokines; Fluoroquinolones; Humans; Immune System; Models, Animal; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2003 |
2 trial(s) available for moxifloxacin and trovafloxacin
Article | Year |
---|---|
Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
Topics: Acute Disease; Adult; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Maxillary Sinusitis; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Prospective Studies; Quinolines; Treatment Outcome | 2003 |
Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Clarithromycin; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Naphthyridines; Pneumonia, Bacterial; Quinolines; Retrospective Studies; Treatment Outcome | 2003 |
46 other study(ies) available for moxifloxacin and trovafloxacin
Article | Year |
---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
Topics: Animals; Antimalarials; Antiparasitic Agents; Cell Line; Drug Design; Fibroblasts; Fluoroquinolones; Humans; Inhibitory Concentration 50; Plasmodium; Quantitative Structure-Activity Relationship; Toxoplasma | 2004 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
Topics: Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Streptococcus agalactiae; Taiwan | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
Topics: Anti-Bacterial Agents; Bacteria; DNA Gyrase; Enzyme Inhibitors; Microbial Sensitivity Tests; Naphthyridines | 2017 |
Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; HEK293 Cells; Humans; Microbial Sensitivity Tests; Rifamycins; Staphylococcus aureus | 2022 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship | 2022 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin | 1998 |
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bordetella; Bordetella pertussis; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 1998 |
Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Streptococcus pneumoniae | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Oxazoles; Oxazolidinones; Quinolines; Staphylococcal Infections; Staphylococcus; Virginiamycin | 1999 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteroides fragilis; Fluoroquinolones; Lactams; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Virginiamycin | 1999 |
Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Cephalosporins; Disease Models, Animal; Fluoroquinolones; Immunoenzyme Techniques; Lipopolysaccharides; Meningitis, Pneumococcal; Moxifloxacin; Naphthyridines; Polysaccharides, Bacterial; Quinolines; Rabbits; Reference Values; Rifabutin; Teichoic Acids; Virginiamycin | 1999 |
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Reserpine; Staphylococcus aureus; Streptococcus pneumoniae | 2000 |
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Microbial; Drug Therapy, Combination; Erythromycin; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Oxazoles; Oxazolidinones; Quinolines; Streptococcus; Virginiamycin | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
Activities of antimicrobial agents against intracellular pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Fluoroquinolones; Gentamicins; Humans; Ketolides; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Penicillin G; Quinolines; Rifampin; Streptococcus pneumoniae; Tumor Cells, Cultured | 2000 |
Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Microbial; Drug Therapy, Combination; Fluoroquinolones; Gram-Positive Bacteria; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Oxazolidinones; Quinolines; Taiwan; Virginiamycin | 2000 |
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Klebsiella; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Urinary Tract Infections | 2000 |
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Topics: Albumins; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Globulins; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Suppuration | 2000 |
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Legionella; Legionellosis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifampin | 2001 |
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Quinolines; Selection, Genetic; Serotyping; Streptococcus pneumoniae | 2001 |
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2001 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Drug Resistance; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Penicillins; Quinolines; Streptococcal Infections; Streptococcus | 2001 |
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Streptococcus pneumoniae | 2002 |
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Aza Compounds; Bacteremia; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Ertapenem; Fluoroquinolones; Gemifloxacin; Humans; Indoles; Lactams; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 2002 |
In vitro activities of newer quinolones against bacteroides group organisms.
Topics: Anti-Infective Agents; Aza Compounds; Bacteroides; Bacteroides fragilis; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Indoles; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 2002 |
In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Genes, Bacterial; Gonorrhea; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Nalidixic Acid; Naphthyridines; Neisseria gonorrhoeae; Ofloxacin; Quinolines | 2003 |
Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Enterobacteriaceae; Enterococcus faecalis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2004 |
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Moxifloxacin; Mutagenicity Tests; Naphthyridines; Ofloxacin; Quinolines; Selection, Genetic; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |
Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
Topics: Anti-Infective Agents; Aza Compounds; Bacteroides fragilis; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines | 2005 |